ArticleInvestigational new drugs2015

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours.

Haruo Iguchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.